transmembrane 4 L six family member 5Genealiases: []
Q-omics provides the consensus-scored TM4SF5 profile across patient tissues and cancer cell-line models. TM4SF5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TM4SF5 is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, TM4SF5 RNA expression shows 11,941 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KIRP, and TGCT as cancer lineages where TM4SF5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TM4SF5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TM4SF5 survival associations across molecular data types. TM4SF5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TM4SF5 RNA expression–survival associations across cancer types. High TM4SF5 expression shows unfavorable associations in ACC, UVM, LGG and ESCA, but favorable associations in KIRC and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TM4SF5 RNA expression.
This table summarizes TM4SF5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRP for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TM4SF5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TM4SF5 shows lower tumor expression in KIRP, KICH and CHOL and higher tumor expression in KIRC, COAD and LIHC. The KIRP box plot shows higher TM4SF5 RNA expression in normal versus tumor tissue (log2 FC = −1.938, t-test p < 0.001).
This table shows molecular features associated with TM4SF5 in patient tissues and cancer cell lines. In patient samples, TM4SF5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TM4SF5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE.
